Shockwave Therapy Contraindications Explained

Shockwave therapy works well for a wide range of chronic musculoskeletal conditions. But like every medical treatment, it is not appropriate for everyone. Certain medical conditions, medications, and anatomical situations make extracorporeal shockwave therapy (ESWT) – a non-invasive treatment using acoustic pressure waves to stimulate healing – either unsafe or inadvisable.

Whether you are a patient researching treatment options or a provider screening candidates, this guide covers the situations where ESWT should be avoided or used with extra caution. For a related overview, see shockwave therapy side effects.

Absolute Contraindications

These are situations where shockwave therapy should not be performed. The risks clearly outweigh any potential benefit.

Malignant Tumors in the Treatment Area

ESWT should never be applied over or near a known malignancy. The mechanical stimulation of tissue – including increased blood flow and cellular activity – could theoretically promote tumor growth or metastasis. This is a firm contraindication endorsed by the International Society for Medical Shockwave Treatment (ISMST, 2016 consensus statement).

Open Growth Plates (Skeletally Immature Patients)

In children and adolescents whose growth plates (epiphyseal plates) have not yet closed, ESWT directed at or near these growth centers could disrupt normal bone development. This is the primary reason shockwave therapy is approached cautiously in pediatric populations. Providers treating teenagers typically confirm growth plate closure via X-ray before proceeding.

Pregnancy (Treatment Near the Uterus or Fetus)

ESWT should not be applied to the abdomen, pelvis, or lower back of pregnant patients. While treatment to a distal extremity (such as the foot or elbow) is likely low-risk, most providers err on the side of caution and defer all ESWT until after delivery.

Blood Clotting Disorders

Patients with hemophilia or other bleeding disorders face elevated risk of hemorrhage or significant bruising from the micro-trauma that ESWT produces in tissue. This is an absolute contraindication in most clinical guidelines.

Active Infection in the Treatment Area

Applying shockwave energy over an area with an active infection (skin infection, cellulitis, osteomyelitis) can spread the infection or worsen inflammation. Treatment should wait until the infection has fully resolved.

Relative Contraindications

These are situations where ESWT may be possible but requires careful evaluation, modified protocols, or additional precautions. The decision is made case by case in consultation between the provider and patient.

Anticoagulant or Antiplatelet Medication

Patients taking blood thinners (warfarin, apixaban, rivaroxaban, clopidogrel) have an increased risk of bruising and superficial bleeding at the treatment site. Some providers will proceed with lower energy settings and careful monitoring, while others defer treatment. Coordination with the prescribing physician is recommended.

Treatment Near Major Nerves or Blood Vessels

Shockwave energy applied near major neurovascular bundles can cause transient nerve irritation or, rarely, vascular damage. Providers should have a thorough understanding of the relevant anatomy and use imaging guidance when treating near sensitive structures.

Treatment Near the Lungs

Applying ESWT to the upper back or thoracic region carries a theoretical risk of pneumothorax (lung collapse) if the shockwave energy penetrates the pleural space. This risk is small but real, particularly with focused high-energy devices. Providers should avoid treating within the thoracic danger zone.

Prosthetic Joints and Metal Implants

The interaction between shockwave energy and metal hardware is not fully understood. Concerns include implant loosening and unpredictable energy reflection. Most providers avoid direct treatment over implants but may treat areas anatomically distant from the hardware.

Recent Corticosteroid Injection

Cortisone injections temporarily weaken connective tissue. Applying ESWT too soon after an injection may increase the risk of tendon damage. The standard recommendation is to wait at least 6 weeks after a corticosteroid injection before beginning shockwave therapy (Speed, 2014, Clinical Rehabilitation).

Condition-Specific Cautions

Beyond the standard contraindication lists, certain clinical scenarios warrant caution:

• Complete tendon tears. ESWT is designed to stimulate healing in damaged but intact tissue. A fully ruptured tendon requires surgical evaluation, not shockwave therapy.
• Acute injuries. ESWT is most effective for chronic conditions (typically present for 3 months or more). Applying it to an acute injury in the inflammatory phase is not supported by evidence and may worsen symptoms.
• Centralized pain syndromes. Conditions like fibromyalgia involve nervous system sensitization rather than localized tissue pathology. ESWT targets tissue-level healing mechanisms and is unlikely to address centralized pain effectively.

What to Tell Your Provider Before Treatment

To help your provider screen for contraindications, be prepared to disclose:

1. All medications, especially blood thinners, antiplatelet agents, and recent corticosteroid injections
2. Implant history, including joint replacements, screws, plates, or cardiac devices
3. Pregnancy status or possibility of pregnancy
4. Bleeding disorders or history of abnormal bruising
5. Active infections or skin conditions in the treatment area
6. Cancer history, including current or recent malignancies

Qualified shockwave therapy providers will conduct a thorough intake that covers these items, but patients should also be proactive about sharing relevant medical history.

The Bottom Line

Shockwave therapy is safe for the majority of patients with chronic musculoskeletal conditions. However, a responsible provider will screen for absolute and relative contraindications before beginning treatment. If any of the situations described above apply to you, discuss them openly with your provider. The goal is effective treatment delivered safely – and that starts with honest communication about your medical history.

References

1. International Society for Medical Shockwave Treatment (ISMST). Consensus statement on ESWT indications and contraindications. 2016. Available at: https://www.shockwavetherapy.org/

2. Speed CA. Extracorporeal shockwave therapy in the management of chronic soft-tissue conditions. J Bone Joint Surg Br. 2004;86(2):165-171. PubMed

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Shockwave therapy outcomes vary by individual and condition. Consult a qualified healthcare provider to determine if shockwave therapy is appropriate for your situation.